Crispr Therapeutics AG (CRSP)
CRISPR Therapeutics AG (CRSP) Exceeds Market Returns: Some Facts to Consider
In the closing of the recent trading day, CRISPR Therapeutics AG (CRSP) stood at $48.81, denoting a +2.61% move from the preceding trading day.
A Turning Point For Crispr Therapeutics As Commercial Growth Accelerates
CRISPR Therapeutics AG (CRSP) is rated Buy, with a 12-month price target of $64.58, driven by CASGEVY's commercial ramp and a robust pipeline. CASGEVY's increasing patient initiations and revenue growth provide a near-term path to profitability, with a strong foundation for future expansion. CRSP's in vivo cardiovascular pipeline, notably CTX310 and CTX320/321, targets large, underserved markets with disruptive one-time gene therapies.
I Expect Crispr Therapeutics To Break Out As 2026 Revenue Exceeds Expectations
Crispr Therapeutics AG is positioned for a revenue inflection as Casgevy ramps in 2026, following earlier FDA/EMA approvals for SCD and TDT. Analysts are underestimating the Casgevy revenue ramp. CRSP now trades at the low end of its 4-year range, despite risk mitigation, a very promising pipeline, and a robust balance sheet, creating a compelling entry point. Casgevy's efficacy is very strong, with >90% response rates, but uptake has lagged due to burdensome preconditioning and patient concerns.
Why CRISPR Therapeutics AG (CRSP) Outpaced the Stock Market Today
CRISPR Therapeutics AG (CRSP) closed the most recent trading day at $47.09, moving +1.42% from the previous trading session.
CRISPR Therapeutics AG (CRSP) Is a Trending Stock: Facts to Know Before Betting on It
CRISPR Therapeutics (CRSP) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
CRISPR Therapeutics AG (CRSP) Registers a Bigger Fall Than the Market: Important Facts to Note
The latest trading day saw CRISPR Therapeutics AG (CRSP) settling at $46.93, representing a -1.59% change from its previous close.
CRISPR Therapeutics AG (CRSP) Falls More Steeply Than Broader Market: What Investors Need to Know
The latest trading day saw CRISPR Therapeutics AG (CRSP) settling at $47.69, representing a -4.79% change from its previous close.
From $49 to $110: Why Piper Sandler Thinks CRSP Can More Than Double From Here
CRISPR Therapeutics (NASDAQ:CRSP) has had a rough stretch lately.
Investors Heavily Search CRISPR Therapeutics AG (CRSP): Here is What You Need to Know
Zacks.com users have recently been watching CRISPR Therapeutics (CRSP) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Here is What to Know Beyond Why CRISPR Therapeutics AG (CRSP) is a Trending Stock
Recently, Zacks.com users have been paying close attention to CRISPR Therapeutics (CRSP). This makes it worthwhile to examine what the stock has in store.
CRISPR Therapeutics Gains After Earnings as Pipeline Hope Grows
CRISPR Therapeutics AG NASDAQ: CRSP stock is up more than 12% after the gene editing pioneer reported its Q4 2025 earnings on Feb. 13. At first glance, that may seem contradictory.
Crispr Therapeutics: Very High Risk But Even Higher Potential Reward
CRISPR Therapeutics is rated 'Buy' for its blockbuster CASGEVY launch, robust cash position, and high upside despite significant risks. CASGEVY's gene-editing therapy targets severe SCD and TDT, with modeled 2030 peak sales of $5.8B and orphan exclusivity until 2031. DCF-based fair value is $91.95, implying 73% upside with 57% revenue CAGR 2026-2035, but more conservative scenarios suggest CRSP might be fairly valued.
